Enhanced biopharmaceutical performance of rivaroxaban through polymeric amorphous solid dispersion

S Metre, S Mukesh, SK Samal, M Chand… - Molecular …, 2018 - ACS Publications
Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …
被引用次数：66 相关文章

[引用][C] Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion

S Metre, S Mukesh, SK Samal, M Chand… - Molecular …, 2018 - cir.nii.ac.jp
Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous
Solid Dispersion | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.

S Metre, S Mukesh, SK Samal, M Chand… - Molecular …, 2018 - europepmc.org
Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …

Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion

S Metre, S Mukesh, SK Samal… - Molecular …, 2018 - pubmed.ncbi.nlm.nih.gov
Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …